• Contact us
  • E-Submission

Ewha Med J : The Ewha Medical Journal

OPEN ACCESS
mobile search button mobile menu button
Search
Advanced Search
ABOUT
BROWSE ARTICLES
JOURNAL POLICIES
FOR CONTRIBUTORS

Articles

Page Path

Case Report

Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis

Sang Il Choi, Sun Seob Park, Eun Jeong Ko, Si Won Lee, Mihong Choi, Kiwon Kim
The Ewha Medical Journal 2014;37(Suppl):S5-S9. Published online: December 24, 2014

Department of Internal Medicine, National Cancer Center, Goyang, Korea.

Corresponding author: Kiwon Kim. Department of Internal Medicine, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea. Tel: 82-31-920-1679, Fax: 82-31-920-0209, kiwonkim@ncc.re.kr
• Received: May 9, 2014   • Accepted: July 1, 2014

Copyright © 2014, The Ewha Medical Journal

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 29 Views
  • 0 Download
prev

Full Article

  • Small cell lung cancer is primarily treated with chemotherapy. For patients with end-stage renal disease (ESRD), systemic chemotherapy is often challenging since renal excretion of chemotherapeutic agents might be decreased due to impaired renal function, leading to increased toxicity. No consensus is made so far regarding appropriate dosage and combination of chemotherapeutic agents for patients on hemodialysis. We report two cases of chemotherapy without significant toxicity in small cell lung cancer patients who were on hemodialysis for ESRD.
  • Keywords: Small cell lung carcinoma; Drug therapy; Kidney failure, chronic; Renal dialysis
  • 1. Na SY, Sung JY, Chang JH, Kim S, Lee HH, Park YH, et al. Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol 2011;33:121-130.
  • 2. Oguri T, Shimokata T, Inada M, Ito I, Ando Y, Sasaki Y, et al. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Cancer Chemother Pharmacol 2010;66:813-817.
  • 3. Kim DM, Kim HL, Chung CH, Park CY. Successful treatment of small-cell lung cancer with irinotecan in a hemodialysis patient with end-stage renal disease. Korean J Intern Med 2009;24:73-75.
  • 4. Takezawa K, Okamoto I, Fukuoka M, Nakagawa K. Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis. J Thorac Oncol 2008;3:1073-1075.
  • 5. Tanizawa K, Fukunaga K, Okumura N, Sugimura M, Tanaka E, Hajiro T, et al. Successful chemotherapy for small-cell lung cancer in an elderly patient undergoing continuous ambulatory peritoneal dialysis. Intern Med 2010;49:1179-1183.
  • 6. Hiraike M, Hiraki Y, Misumi N, Hanada K, Tsuji Y, Kamimura H, et al. Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer. Cancer Chemother Pharmacol 2012;69:845-848.
  • 7. Murakami K, Akutsu Y, Miyazawa Y, Shuto K, Shiratori T, Uesato M, et al. A case of small-cell esophageal cancer with chronic renal failure undergoing hemodialysis safely treated with cisplatin and etoposide. Esophagus 2011;8:209-215.
  • 8. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
  • 9. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010;21:1395-1403.
  • 10. Schmittel A, Sebastian M, Fischer von, Martus P, Gauler TC, Kaufmann C, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol 2011;22:1798-1804.
Fig. 1
Positron emission tomography at the time of initial diagnosis (A), after 3 cycles of treatment (B), after 6 cycles of treatment (C), and 6 weaks after the treatment completion (D).
emj-37-S5-g001.jpg
Fig. 2
Treatment course from the time of diagnosis of case 2. PR, partial response; PD, progression of disease.
emj-37-S5-g002.jpg

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      Download Citation

      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:

      Include:

      Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis
      Ewha Med J. 2014;37(Suppl):S5-S9.   Published online December 24, 2014
      DOI: https://doi.org/10.12771/emj.2014.37.S.S5
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis
      Ewha Med J. 2014;37(Suppl):S5-S9.   Published online December 24, 2014
      DOI: https://doi.org/10.12771/emj.2014.37.S.S5
      Close

      Figure

      • 0
      • 1
      Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis
      Image Image
      Fig. 1 Positron emission tomography at the time of initial diagnosis (A), after 3 cycles of treatment (B), after 6 cycles of treatment (C), and 6 weaks after the treatment completion (D).
      Fig. 2 Treatment course from the time of diagnosis of case 2. PR, partial response; PD, progression of disease.

      Fig. 1

      Fig. 2

      Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis
      Ewha Med J : The Ewha Medical Journal

      ABOUT

      BROWSE ARTICLES 

      JOURNAL POLICIES

      FOR CONTRIBUTORS 

      © Ewha Womans University College of Medicine.
      TOP